BRIEF-Viracta Therapeutics Announces Presentation Of Updated Phase 2 Data At Ash 2020 And Productive Outcome Of Its Recent End Of Phase 2 Meeting With FDA

Reuters
07 Dec 2020

Dec 7 (Reuters) - Sunesis Pharmaceuticals Inc :

* VIRACTA THERAPEUTICS ANNOUNCES PRESENTATION OF UPDATED PHASE 2 DATA AT ASH 2020 AND PRODUCTIVE OUTCOME OF ITS RECENT END OF PHASE 2 MEETING WITH FDA

* VIRACTA THERAPEUTICS - REGISTRATION TRIAL FOR TREATMENT OF RELAPSED/REFRACTORY EBV+ LYMPHOMAS TO BEGIN IN 1H2021

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10